1
|
Jonker AH, O’Connor D, Cavaller-Bellaubi M, Fetro C, Gogou M, ’T Hoen PAC, de Kort M, Stone H, Valentine N, Pasmooij AMG. Drug repurposing for rare: progress and opportunities for the rare disease community. Front Med (Lausanne) 2024; 11:1352803. [PMID: 38298814 PMCID: PMC10828010 DOI: 10.3389/fmed.2024.1352803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2023] [Accepted: 01/05/2024] [Indexed: 02/02/2024] Open
Abstract
Repurposing is one of the key opportunities to address the unmet rare diseases therapeutic need. Based on cases of drug repurposing in small population conditions, and previous work in drug repurposing, we analyzed the most important lessons learned, such as the sharing of clinical observations, reaching out to regulatory scientific advice at an early stage, and public-private collaboration. In addition, current upcoming trends in the field of drug repurposing in rare diseases were analyzed, including the role these trends could play in the rare diseases' ecosystem. Specifically, we cover the opportunities of innovation platforms, the use of real-world data, the use of artificial intelligence, regulatory initiatives in repurposing, and patient engagement throughout the repurposing project. The outcomes from these emerging activities will help progress the field of drug repurposing for the benefit of patients, public health and medicines development.
Collapse
Affiliation(s)
- Anneliene Hechtelt Jonker
- Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Enschede, Netherlands
- International Rare Diseases Research Consortium, Paris, France
| | - Daniel O’Connor
- International Rare Diseases Research Consortium, Paris, France
- ABPI, London, United Kingdom
| | - Maria Cavaller-Bellaubi
- International Rare Diseases Research Consortium, Paris, France
- EURORDIS-Rare Diseases Europe, Paris, France
| | - Christine Fetro
- International Rare Diseases Research Consortium, Paris, France
- Fondation Maladies Rares, Paris, France
| | - Maria Gogou
- International Rare Diseases Research Consortium, Paris, France
- Department of Neurology, Great Ormond Street Hospital for Children, London, United Kingdom
| | - Peter A. C. ’T Hoen
- International Rare Diseases Research Consortium, Paris, France
- Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, Netherlands
| | - Martin de Kort
- International Rare Diseases Research Consortium, Paris, France
- EATRIS ERIC, European Infrastructure for Translational Medicine, Amsterdam, Netherlands
| | - Heather Stone
- International Rare Diseases Research Consortium, Paris, France
- CURE ID, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MA, United States
| | - Nivedita Valentine
- International Rare Diseases Research Consortium, Paris, France
- Global Product Innovation, Pharmanovia, Value Added Medicines Committee, Medicines for Europe, Basildon, United Kingdom
| | - Anna Maria Gerdina Pasmooij
- International Rare Diseases Research Consortium, Paris, France
- Dutch Medicines Evaluation Board, Utrecht, Netherlands
| |
Collapse
|
2
|
Deplanque D, Fetro C, Ferry A, Lechat P, Beghyn T, Bernard C, Bernasconi A, Bienayme H, Cougoule C, Del Bano J, Demiot C, Lebrun-Vignes B. Repositionnement des médicaments : de la découverte d’un effet pharmacologique utile à la mise à disposition du traitement pour le patient. Therapie 2023; 78:1-9. [PMID: 36564262 DOI: 10.1016/j.therap.2022.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 11/21/2022] [Indexed: 12/12/2022]
Affiliation(s)
- Dominique Deplanque
- Université Lille, Inserm, CHU Lille, centre d'investigation clinique (CIC) 1403, 59000 Lille, France.
| | | | | | - Philippe Lechat
- Université Paris-cité, service de pharmacologie et toxicologie, hôpital européen Georges-Pompidou, 75015 Paris, France; Agence générale des équipements et des produits de santé (AGEPS), Assistance publique-Hôpitaux de Paris, 75005 Paris, France
| | - Terence Beghyn
- APTEEUS SAS, campus Institut Pasteur, 59000 Lille, France
| | - Claude Bernard
- Agence générale des équipements et des produits de santé (AGEPS), Assistance publique-Hôpitaux de Paris, 75005 Paris, France
| | | | | | - Céline Cougoule
- Institut de pharmacologie et de biologie structurale (IPBS), université de Toulouse, CNRS, université Toulouse III - Paul-Sabatier (UPS), 31400 Toulouse, France
| | - Joanie Del Bano
- Aix-Marseille université, AP-HM, Inserm, DHUNE, Inst Neurosci Syst, service de pharmacologie clinique et pharmacovigilance, Thelonius Mind, 13000 Marseille, France
| | - Claire Demiot
- UR 20218-NeurIT, faculties of medicine and pharmacy, university of Limoges, 87025 Limoges, France
| | - Bénédicte Lebrun-Vignes
- Service de pharmacologie et centre régional de pharmacovigilance, hôpital Pitié-Salpêtrière, groupe hospitalier, AP-HP, Sorbonne université, 75013 Paris, France
| |
Collapse
|
3
|
Deplanque D, Fetro C, Ferry A, Lechat P, Beghyn T, Bernard C, Bernasconi A, Bienayme H, Cougoule C, Del Bano J, Demiot C, Lebrun-Vignes B. Drug repurposing: From the discovery of a useful pharmacological effect to making the treatment available to the patient. Therapie 2023; 78:10-18. [PMID: 36528417 DOI: 10.1016/j.therap.2022.11.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 11/21/2022] [Indexed: 12/07/2022]
Abstract
The repurposing of a medicine already on the market to a new indication could be an opportunity to respond rapidly to a therapeutic need not yet covered, particularly in the context of rare and neglected diseases, or health emergencies. However, at each stage, difficulties may arise that will prevent the repurposed drug from being provided to patients. Beyond fortuity or a systematic strategy to detect a useful pharmacological effect, the implementation of the preclinical and clinical stages is sometimes complicated by the difficulty of accessing the molecule and its pharmaceutical data. Furthermore, relevant clinical results will not always be sufficient to ensure that a marketing authorisation is obtained or that patients receive satisfactory care. In addition to describing these various obstacles, the round table provided an opportunity to put forward recommendations for overcoming them, in particular the creation of a public-private partnership structure with sufficient funding to be able to offer individualised support for projects up to and including the marketing application.
Collapse
Affiliation(s)
- Dominique Deplanque
- Université Lille, Inserm, CHU Lille, centre d'investigation clinique (CIC) 1403, 59000 Lille, France.
| | | | | | - Philippe Lechat
- Université Paris-cité, service de pharmacologie et toxicologie, hôpital européen Georges-Pompidou, 75015 Paris, France; Agence générale des équipements et des produits de santé (AGEPS), Assistance publique-Hôpitaux de Paris, 75005 Paris, France
| | - Terence Beghyn
- APTEEUS SAS, campus Institut Pasteur, 59000 Lille, France
| | - Claude Bernard
- Agence générale des équipements et des produits de santé (AGEPS), Assistance publique-Hôpitaux de Paris, 75005 Paris, France
| | | | | | - Céline Cougoule
- Institut de pharmacologie et de biologie structurale (IPBS), université de Toulouse, CNRS, université Toulouse III - Paul-Sabatier (UPS), 31400 Toulouse, France
| | - Joanie Del Bano
- Aix-Marseille université, AP-HM, Inserm, DHUNE, Inst Neurosci Syst, service de pharmacologie clinique et pharmacovigilance, Thelonius Mind, 13000 Marseille, France
| | - Claire Demiot
- UR 20218-NeurIT, faculties of medicine and pharmacy, university of Limoges, 87025 Limoges, France
| | - Bénédicte Lebrun-Vignes
- Service de pharmacologie et centre régional de pharmacovigilance, hôpital Pitié-Salpêtrière, groupe hospitalier, AP-HP, Sorbonne université, 75013 Paris, France
| |
Collapse
|
4
|
Abstract
While more than 7000 rare diseases have been identified, only about 5 percent benefit from a licensed treatment. As the majority of these diseases is life threatening, these facts underscore the need for new drugs. Drug repositioning is an alternative strategy in drug development, which represents an attractive opportunity for rare diseases. Drug repositioning (also called drug repurposing, drug reprofiling or drug re-tasking) consists in identifying for an already approved or investigational drug a new use outside the scope of the original medical indication. Drug repositioning is considered in the field of orphan drugs as being a faster and somehow less costly strategy than traditional new drug development for pharmaceutical companies. While several successful repositioning cases have been discovered by serendipity, most successes straightly derive from the molecular characterization of the concerned disease. This short commentary is mainly dedicated to these rationally-based success stories.
Collapse
Affiliation(s)
- Daniel Scherman
- French foundation for rare diseases, 75014 Paris, France; Chemical and biological technologies for health unit (UTCBS), CNRS UMR8258, 75006 Paris, France; UTCBS, Inserm U1267, 75006 Paris, France; Faculté de pharmacie, université Paris Descartes, université de Paris, 75006 Paris, France.
| | | |
Collapse
|
5
|
Drieskens S, Anseeuw K, Annemans L, Fetro C. Belgian cost-effectiveness analysis of hydroxocobalamin (Cyanokit) in known or suspected cyanide poisoning. Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2012-000213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|